Zollinger‑Ellison‑type Gastrin‑Producing Adenoma
Overview
Zollinger‑Ellison syndrome (ZES) is a rare disorder caused by a gastrin‑producing tumor—most often a gastrinoma—that originates in the pancreas or duodenum. The tumor secretes excessive amounts of gastrin, a hormone that stimulates the stomach to produce acid. The resulting hyperacidity can lead to recurrent peptic ulcers, diarrhea, and malabsorption.
- Prevalence: Approximately 1–3 cases per million people worldwide; about 70 % are associated with multiple endocrine neoplasia type 1 (MEN 1) [1].
- Age: Average diagnosis age is 40–50 years, but cases range from childhood (especially in MEN 1) to the elderly.
- Sex: Slight male predominance (≈55 % male) but overall distribution is fairly even.
Because the condition is uncommon, many patients experience delays in diagnosis. Early recognition and treatment are essential to prevent serious complications.
Symptoms
Symptoms result from chronic high stomach acid and the tumor’s mass effect. Not every patient has all of them.
Gastro‑intestinal (GI) symptoms
- Recurrent peptic ulcer disease: Ulcers often occur in atypical locations (duodenum beyond the first part, jejunum, or even the esophagus) and may be resistant to standard therapy.
- Abdominal pain: Burning or gnawing pain that may improve with meals or antacids.
- Diarrhea: Occurs in up to 50 % of patients; sometimes watery and profuse due to acid inactivation of pancreatic enzymes.
- Steatorrhea (fatty stools): Malabsorption of fats can cause pale, foul‑smelling stools.
- Nausea / vomiting: May be triggered by ulcer pain or severe acid reflux.
- Gastro‑esophageal reflux disease (GERD): Persistent heartburn caused by excess acid.
Systemic symptoms
- Weight loss: Resulting from malabsorption, decreased appetite, or chronic diarrhea.
- Fatigue / anemia: Chronic blood loss from ulcerations can lead to iron‑deficiency anemia.
- Bone pain or fractures: Long‑standing acid excess can impair calcium absorption.
Symptoms related to tumor location
- Pancreatic gastrinoma: May cause a palpable mass, back pain, or jaundice if the bile duct is compressed.
- Duodenal gastrinoma: Often small and may not cause a palpable mass, but can cause obstructive symptoms if it grows large.
Causes and Risk Factors
Most gastrinomas are sporadic, but several identifiable risk factors exist.
Genetic factors
- Multiple Endocrine Neoplasia type 1 (MEN 1): An inherited mutation in the MEN1 tumor suppressor gene. About 20–30 % of patients with ZES have MEN 1, and 70 % of MEN 1 patients develop gastrinomas.
- Familial isolated gastrinoma: Rare autosomal dominant inheritance without other MEN 1 features.
Other risk factors
- Age: Incidence rises after age 30, with a peak in the fifth decade.
- Gender: Slight male predominance may reflect referral patterns rather than true biological risk.
- Chronic atrophic gastritis / H. pylori infection: These conditions increase basal gastrin levels but do not cause gastrinomas; they may mask or complicate diagnosis.
Diagnosis
Because symptoms overlap with common peptic ulcer disease, a systematic approach is required.
Clinical suspicion
- Refractory ulcers (persist after >8 weeks of therapy) or ulcers in unusual locations.
- Persistent diarrhea or steatorrhea without other obvious cause.
- History of MEN 1 or a family member with gastrinoma.
Laboratory tests
- Fasting serum gastrin level: A level >1000 pg/mL (normal <100 pg/mL) is highly suggestive, especially if gastric pH <2.
- Secretin stimulation test: In ZES, gastrin paradoxically rises >120 pg/mL after IV secretin (normally it falls).
- Acid output measurement (gastric pH): Confirming hyperacidity (pH ≤2).
- Complete blood count (CBC): To evaluate anemia.
Imaging studies
- Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT: Highly sensitive for locating gastrinomas, especially small (<1 cm) lesions.
- CT scan (multiphase contrast) or MRI of abdomen: Identifies pancreatic or duodenal masses and assesses liver metastasis.
- Endoscopic ultrasound (EUS): Provides detailed images of small pancreatic lesions and allows fine‑needle aspiration for pathology.
- Upper endoscopy (EGD): Visualizes ulcer disease and may obtain biopsies to rule out malignancy.
Pathology
If a lesion is resected, histology confirms a well‑differentiated neuroendocrine tumor (NET) with positive chromogranin A and synaptophysin staining.
Treatment Options
1. Acid‑suppression therapy (first‑line)
- Proton‑pump inhibitors (PPIs): High‑dose omeprazole (e.g., 60 mg BID) or equivalent. PPIs are the cornerstone, controlling acid hypersecretion and healing ulcers in >90 % of patients.
- Histamine‑2 receptor antagonists (H2 blockers): Occasionally used as adjuncts, but less effective for ZES.
- Therapy is usually lifelong unless the tumor is completely removed.
2. Surgical resection
- Curative intent: Enucleation or pancreaticoduodenectomy (Whipple) for localized disease.
- Debulking surgery: Reduces tumor burden when metastases are present; may improve symptom control and decrease PPI requirement.
- Success rates: 60–80 % achieve long‑term remission when the tumor is solitary and confined.
3. Medical therapies for unresectable or metastatic disease
- Somatostatin analogues (octreotide, lanreotide): Inhibit gastrin secretion and may shrink tumor size.
- Targeted therapy (everolimus, sunitinib): Approved for progressive pancreatic neuroendocrine tumors; data for gastrinomas are emerging.
- Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE: Shows promise in controlling hormone secretion and disease progression.
4. Management of metastases
- Liver‑directed therapies: Radiofrequency ablation, chemo‑embolization, or surgical resection of hepatic lesions.
- Systemic chemotherapy: Rarely needed; regimens such as streptozocin + 5‑FU are reserved for aggressive disease.
5. Lifestyle and supportive measures
- Low‑fat diet to lessen steatorrhea.
- Small, frequent meals to reduce acid spikes.
- Calcium and vitamin D supplementation if malabsorption is present.
- Regular monitoring of bone density (DEXA) in long‑term patients.
Living with Zollinger‑Ellison‑type Gastrin‑Producing Adenoma
Managing ZES is a lifelong partnership between you, your gastroenterologist, endocrinologist, and surgeon.
Medication adherence
- Take PPIs exactly as prescribed—most patients need twice‑daily dosing.
- Never stop therapy abruptly; taper only under medical supervision to avoid rebound hyperacidity.
Nutrition
- Eat small, balanced meals every 3–4 hours.
- Limit spicy, acidic, and fatty foods that can aggravate symptoms.
- Incorporate a high‑protein, low‑fat diet** if you have steatorrhea; consider medium‑chain triglyceride (MCT) oils which are easier to absorb.
- Stay hydrated—diarrhea can cause electrolyte loss.
Regular follow‑up
- Serum gastrin levels: every 6–12 months (or sooner after any change in therapy).
- Imaging (CT, MRI, or PET): annually to monitor for recurrence or metastasis.
- Bone health: DEXA scan every 2–3 years if you have chronic malabsorption.
Psychosocial wellbeing
- Join support groups (e.g., NET Patient Foundation) for shared experiences.
- Consider counseling to manage anxiety related to chronic disease.
Prevention
Because most gastrinomas are sporadic, primary prevention is limited. However, risk can be reduced in known high‑risk groups:
- Genetic counseling: Individuals with MEN 1 mutations should undergo regular screening (annual fasting gastrin, imaging) starting in adolescence.
- Avoid chronic PPI overuse in low‑risk individuals: Over‑suppression of acid does not prevent gastrinomas and can mask early symptoms.
- Healthy lifestyle: While it does not prevent tumor formation, maintaining a balanced diet and normal weight supports overall GI health.
Complications
If untreated or inadequately controlled, ZES can lead to serious health problems:
- Gastro‑intestinal bleeding: From ulcer erosion; may require transfusion or endoscopic therapy.
- Perforated ulcer: A surgical emergency with a mortality rate up to 20 % if delayed.
- Severe malabsorption: Leading to protein‑calorie deficiency, electrolyte disturbances, and osteoporosis.
- Liver metastasis: Occurs in 30–50 % of patients; associated with reduced survival (median 5–10 years).
- Refractory diarrhea: Can cause dehydration, renal insufficiency, and electrolyte imbalance (hypokalemia, metabolic alkalosis).
- Quality‑of‑life decline: Chronic pain, frequent medication, and dietary restrictions may affect work and social life.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden, severe abdominal pain that does not improve with antacids or pain medication.
- Vomiting blood (bright red or “coffee‑ground” material) or passing black, tarry stools (melena).
- Persistent vomiting with inability to keep fluids down, leading to dehydration.
- Rapid heart rate, fainting, or confusion (signs of severe blood loss or electrolyte disturbance).
- Sudden onset of high‑grade fever with abdominal pain—possible ulcer perforation and infection.
These signs may indicate ulcer bleeding, perforation, or severe electrolyte imbalance, all of which require immediate medical attention.
References
- Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. https://www.mayoclinic.org
- Cleveland Clinic. “Gastrinoma (Zollinger‑Ellison Syndrome).” 2022. https://my.clevelandclinic.org
- National Institutes of Health (NIH) – National Institute of Diabetes and Digestive and Kidney Diseases. “Zollinger‑Ellison Syndrome.” 2021. https://www.niddk.nih.gov
- World Health Organization. “Classification of Neuroendocrine Tumors.” 2020. https://www.who.int
- Janssen et al. “Long‑term outcomes of surgery for sporadic gastrinoma.” Ann Surg Oncol. 2020;27:4290‑4298.
- Vezzosi et al. “Somatostatin analogues in metastatic gastrinoma: a systematic review.” Endocrine. 2022;77:345‑356.
- U.S. Centers for Disease Control and Prevention. “Rare disease data: Gastrinoma.” 2023. https://www.cdc.gov